WO2000053229A3 - Proteinkonjugate auf basis von lumazinsynthase, verfahren zu deren herstellung und deren verwendung - Google Patents

Proteinkonjugate auf basis von lumazinsynthase, verfahren zu deren herstellung und deren verwendung Download PDF

Info

Publication number
WO2000053229A3
WO2000053229A3 PCT/EP2000/001899 EP0001899W WO0053229A3 WO 2000053229 A3 WO2000053229 A3 WO 2000053229A3 EP 0001899 W EP0001899 W EP 0001899W WO 0053229 A3 WO0053229 A3 WO 0053229A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
icosahedral
peptide
producing
dna fragment
Prior art date
Application number
PCT/EP2000/001899
Other languages
English (en)
French (fr)
Other versions
WO2000053229A2 (de
Inventor
Markus Fischer
Adelbert Bacher
Original Assignee
Markus Fischer
Adelbert Bacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Markus Fischer, Adelbert Bacher filed Critical Markus Fischer
Priority to EP00920476A priority Critical patent/EP1181377A2/de
Priority to AU41040/00A priority patent/AU4104000A/en
Publication of WO2000053229A2 publication Critical patent/WO2000053229A2/de
Publication of WO2000053229A3 publication Critical patent/WO2000053229A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Die Erfindung betrifft Proteinkonjugate, Verfahren, Vektoren, Proteine und DNA zu deren Herstellung, sowie deren Verwendung, sowie Arzneimittel oder Impfstoffe mit einem Gehalt derselben. Sie dient zur Herstellung supramolekularer Partikel, welche eine oder mehrere unterschiedliche, willkürlich bestimmbare Struktureinheiten in grosser Anzahl auf der Oberfläche eines einzelnen, etwa kugelförmigen Proteinmoleküls präsentieren. Ikosaedrische Lumazinsynthasen werden als Trägerproteine für Peptide bzw. Proteine eingesetzt. Ein DNA-Fragment, welches für ein Peptidmolekül kodiert, wird unter Verwendung molekularbiologischer Verfahren mit einen DNA-Fragment, welches für eine ikosaedrische Lumazinsynthase kodiert, fusioniert. Das DNA-Fragment wird in einen Klonierungsvektor inseriert und in einen geeigneten Wirtsstamm transformiert. Auf dem Wege der Genexpression wird ein Polypeptid produziert. Bei der Verwendung von bestimmten Peptidstrukturen als Fusionspartner erfolgt im Wirtsstamm eine posttranslationale Veränderung derselben. Das chimäre Peptid wird gereinigt und bei Bedarf chemisch verändert. Desweiteren können durch Vermischung ikosaedrische Moleküle hergestellt werden, die bis zu 120 unterschiedliche Peptidmotive auf deren Oberfläche enthalten. Die entstandenen Verbindungen eignen sich als Hilfsmittel zur Durchführung von Analysenverfahren (ELISA, Biosensoren) oder zur Herstellung von Impfstoffen.
PCT/EP2000/001899 1999-03-08 2000-03-03 Proteinkonjugate auf basis von lumazinsynthase, verfahren zu deren herstellung und deren verwendung WO2000053229A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00920476A EP1181377A2 (de) 1999-03-08 2000-03-03 Proteinkonjugate auf basis von lumazinsynthase, verfahren zu deren herstellung und deren verwendung
AU41040/00A AU4104000A (en) 1999-03-08 2000-03-03 Protein conjugates, methods, vectors, proteins and dna for producing them, theiruse, and medicaments and vaccines containing a certain quantity of said protein conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19910102A DE19910102B4 (de) 1999-03-08 1999-03-08 Proteinkonjugate, Verfahren, Vektoren, Proteine und DNA zu deren Herstellung, deren Verwendung, sowie Arzneimittel und Impfstoffe mit einem Gehalt derselben
DE19910102.7 1999-03-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09936028 A-371-Of-International 2002-01-31
US10/385,415 Continuation US20040014158A1 (en) 1999-03-08 2003-03-10 Protein conjugates, methods, vectors, proteins and DNA for producing them, their use, and medicaments and vaccines containing a certain quantity of said protein conjugates

Publications (2)

Publication Number Publication Date
WO2000053229A2 WO2000053229A2 (de) 2000-09-14
WO2000053229A3 true WO2000053229A3 (de) 2001-11-29

Family

ID=7900086

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/001899 WO2000053229A2 (de) 1999-03-08 2000-03-03 Proteinkonjugate auf basis von lumazinsynthase, verfahren zu deren herstellung und deren verwendung

Country Status (4)

Country Link
EP (1) EP1181377A2 (de)
AU (1) AU4104000A (de)
DE (1) DE19910102B4 (de)
WO (1) WO2000053229A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9711082A (pt) 1996-03-29 2000-01-11 Lawrence Berkeley National Lab Realce de rmn emri na presença de gases mopbres hiperpolarizados.
US7061237B2 (en) 2000-07-13 2006-06-13 The Regents Of The University Of California Remote NMR/MRI detection of laser polarized gases
US6652833B2 (en) * 2000-07-13 2003-11-25 The Regents Of The University Of California Functionalized active-nucleus complex sensor
AR044603A1 (es) 2004-06-03 2005-09-21 Consejo Nac Invest Cient Tec Proteinas quimericas aisladas de lumazina sintetasa modificada para la presentacion multiple de moleculas y sus aplicaciones

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013327A1 (en) * 1992-12-15 1994-06-23 The Wellcome Foundation Limited Immunoreactive reagents employing dihydrofolate reductase
WO1996031617A1 (en) * 1995-04-04 1996-10-10 La Jolla Institute For Allergy And Immunology Method of production of antigen-specific glycosylation inhibiting factor
WO1998018917A2 (en) * 1996-10-28 1998-05-07 Board Of Trustees Michigan State University RIBOFLAVIN MUTANTS AS VACCINES AGAINST $i(ACTINOBACILLUS PLEUROPNEUMONIAE)
US5786179A (en) * 1994-02-28 1998-07-28 Agritech Technologies Ltd. Heterologous protein comprising avian alpha-subunit inhibin protein and methods of producing same
US5876947A (en) * 1997-07-25 1999-03-02 The New York Blood Center, Inc. Monospecific antibody reactive with Fibrinogen and fibrinopeptide B
WO1999026651A1 (en) * 1997-11-25 1999-06-03 Smithkline Beecham Corporation ribH
WO1999027128A1 (en) * 1997-11-25 1999-06-03 Smithkline Beecham Corporation ribH
WO1999038986A2 (en) * 1998-01-30 1999-08-05 Novartis Ag Riboflavin biosynthesis genes from plants and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013327A1 (en) * 1992-12-15 1994-06-23 The Wellcome Foundation Limited Immunoreactive reagents employing dihydrofolate reductase
US5786179A (en) * 1994-02-28 1998-07-28 Agritech Technologies Ltd. Heterologous protein comprising avian alpha-subunit inhibin protein and methods of producing same
WO1996031617A1 (en) * 1995-04-04 1996-10-10 La Jolla Institute For Allergy And Immunology Method of production of antigen-specific glycosylation inhibiting factor
WO1998018917A2 (en) * 1996-10-28 1998-05-07 Board Of Trustees Michigan State University RIBOFLAVIN MUTANTS AS VACCINES AGAINST $i(ACTINOBACILLUS PLEUROPNEUMONIAE)
US5876947A (en) * 1997-07-25 1999-03-02 The New York Blood Center, Inc. Monospecific antibody reactive with Fibrinogen and fibrinopeptide B
WO1999026651A1 (en) * 1997-11-25 1999-06-03 Smithkline Beecham Corporation ribH
WO1999027128A1 (en) * 1997-11-25 1999-06-03 Smithkline Beecham Corporation ribH
WO1999038986A2 (en) * 1998-01-30 1999-08-05 Novartis Ag Riboflavin biosynthesis genes from plants and uses thereof

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BACHER A ET AL: "Biosynthesis of riboflavin: lumazine synthase and riboflavin synthase.", METHODS IN ENZYMOLOGY, 1997, VOL. 280, PART J, PAGE(S) 389-399, XP000938442 *
BACHER A ET AL: "Biosynthesis of riboflavin: Structure and mechanism of lumazine synthase.", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 24, no. 1, 1996, 656th Meeting of the Biochemical Society;Dublin, Ireland; September 11-15, 1995, pages 89 - 94, XP000929906, ISSN: 0300-5127 *
CUSHMAN M ET AL: "Synthesis of 2,6-dioxo-(1H,3H)-9-N-ribitylpurine and lumazine synthase and riboflavin synthase.", BIOORGANIC & MEDICINAL CHEMISTRY, APR 1998, VOL. 6, NO. 4, PAGE(S) 409-15, XP000938434 *
DECKERT G ET AL: "THE COMPLETE GENOME OF THE HYPERTHERMOPHILIC BACTERIUM AQUIFEX AEOLICUS", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 392, 26 March 1998 (1998-03-26), pages 353 - 358, XP000867134, ISSN: 0028-0836 *
GOLDBAUM F A ET AL: "Crystallization and preliminary X-ray diffraction analysis of the lumazine synthase from Brucella abortus.", JOURNAL OF STRUCTURAL BIOLOGY, vol. 123, no. 2, October 1998 (1998-10-01), pages 175 - 178, XP000929914, ISSN: 1047-8477 *
GOLDBAUM, FERNANDO A. ET AL: "The 18-kDa cytoplasmic protein of Brucella species - an antigen useful for diagnosis - is a lumazine synthase", J. MED. MICROBIOL., VOL. 48, NO. 9, PAGE(S) 833-839, September 1999 (1999-09-01), XP000938445 *
JORDAN DB ET AL: "Plant riboflavin biosynthesis. Cloning, chloroplast localization, expression, purification, and partial characterization of spinach lumazine synthase.", JOURNAL OF BIOLOGICAL CHEMISTRY, JUL 30 1999, VOL. 274, NO. 31, PAGE(S) 22114-21, XP002153695 *
MORTL S ET AL: "Biosynthesis of riboflavin. Lumazine synthase of Escherichia coli.", JOURNAL OF BIOLOGICAL CHEMISTRY, DEC 27 1996, VOL. 271, NO. 52, PAGE(S) 33201-7, XP002153694 *
RITSERT KARL ET AL: "Studies on the lumazine synthase/riboflavin synthase complex of Bacillus subtilis: Crystal structure analysis of reconstituted, icosahedral beta-subunit capsids with bound substrate analogue inhibitor at 2.4 A resolution.", JOURNAL OF MOLECULAR BIOLOGY, vol. 253, no. 1, 1995, pages 151 - 167, XP000929904, ISSN: 0022-2836 *
SHERWOOD R: "PROTEIN FUSIONS: BIOSEPARATION AND APPLICATION", TRENDS IN BIOTECHNOLOGY,GB,ELSEVIER PUBLICATIONS, CAMBRIDGE, vol. 9, no. 1, 1991, pages 1 - 3, XP000168479, ISSN: 0167-7799 *
YON J ET AL: "PRECISE GENE FUSION BY PCR", NUCLEIC ACIDS RESEARCH,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 17, no. 12, 26 June 1989 (1989-06-26), pages 4895, XP000268572, ISSN: 0305-1048 *

Also Published As

Publication number Publication date
WO2000053229A2 (de) 2000-09-14
DE19910102B4 (de) 2006-06-01
DE19910102A1 (de) 2000-09-28
EP1181377A2 (de) 2002-02-27
AU4104000A (en) 2000-09-28

Similar Documents

Publication Publication Date Title
WO2005086794A3 (en) Lactobacillus acidophilus nucleic acid sequences encoding stress-related proteins and uses therefor
WO2001002588A3 (en) Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
WO2000053229A3 (de) Proteinkonjugate auf basis von lumazinsynthase, verfahren zu deren herstellung und deren verwendung
WO2005001057A3 (en) Lactobacillus acidophilus nucleic acids encoding fructo-oligosaccharide utilization compounds and uses thereof
WO2002068459A3 (en) Non aggregating fluorescent proteins and methods for using the same
WO2002040683A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002046407A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2001092496A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002016567A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2001088148A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002053717A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2001064919A3 (en) 18036, a novel calpain-like protease and uses thereof
WO2001081413A3 (en) Isolated human transporter proteins, nucleic acids and uses thereof
WO2002046406A3 (en) Human transporter proteins, nucleic acid molecules encoding them,and uses thereof
AU2002234132A1 (en) 13245, a novel human myotonic dystrophy type protein kinase and uses therefor
WO2001068806A3 (en) 26934, a novel cytidine deaminase-like molecule and uses thereof
WO2002022678A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2001064910A3 (en) Atpase-like molecule and uses thereof
WO2002057310A3 (en) Human transporter proteins, nucleic acid molecules encoding them, and uses thereof
WO2002024910A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof
WO2002024748A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002020757A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002046217A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
EP1865061A3 (de) IL-17-homologe Polypeptide und ihre therapeutische Verwendung
AU2001288284A1 (en) 14189, a human kinase and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000920476

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09936028

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000920476

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642